iXensor receives Rohto Pharmaceutical’s investment to boost technology licensing

MobiHealth News April 27, 2022
Adam Ang

The company aims to help the self-testing market grow by licensing its core technology for transforming smartphones into IVD devices.

Taiwanese mobile health developer iXensor has obtained an undisclosed strategic investment from Rohto Pharmaceutical Co. to broaden the access to its core technology that transforms smartphones into IVD devices.

On Wednesday, the company announced that the publicly-listed Japanese pharma company became its latest partner and shareholder who will help expand its business globally and promote its technology licensing business.

Through the partnership, Rohto also aims to expand its testing and diagnostic business by first securing a separate technology licensing and joint development deal with iXensor, providing its Japanese customers access to self-testing tools for women’s health and infectious diseases.

WHY...

Today's Sponsors

Today's Sponsor